Correspondent: Animal Defenders International Millbank Tower, Millbank, London SW1P 4QP, UK
[email protected] To: World Health Organization, national governments, funding bodies, academia and regulators 14 May 2020 A shift in focus is needed to tackle COVID-19 Since the identification of SARS-COV-2, the virus which causes COVID-19, there has been a surge in funding of research and testing to find a vaccine and treatments, with unprecedented collaboration and openness between researchers worldwide. In addition to use of advanced technologies more relevant to humans, such as patient cultures, artificial intelligence and organ-on-a-chip technology some researchers are using animals, including mice, ferrets, primates, guinea pigs, pigs and cats in the UK, US, Netherlands, China and Australia. The World Health Organization-China Joint Mission has advised that the “ideal animal model for studying routes of virus transmission, pathogenesis, antiviral therapy, vaccine and immune responses has yet to be found”, and yet significant funding and precious time is being spent on animal research. This is despite the known species differences which make the results from such data unreliable when translated to humans. For example, mice are one of the most commonly used species in drug and vaccine research. In addition to major differences between human and mouse respiratory systems, species differences specific to research for SARS-COV-2 include that mice do not naturally have the same receptors the virus uses to infect human cells. Researchers are now attempting to “humanize” mice to ensure they contract the virus. Such fundamental differences risk impeding the production of vaccines and other treatments to help prevent and reduce the symptoms of COVID-19 in people.